NCT05110170View on ClinicalTrials.gov

Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®

PHASE3CompletedINTERVENTIONAL
Enrollment

188

Participants

Timeline

Start Date

October 15, 2020

Primary Completion Date

April 5, 2022

Study Completion Date

June 24, 2022

Conditions
Breast Cancer
Interventions
DRUG

LY01005

LY01005 was administered as 3 intramuscular (IM) injections, 28 days apart. As concomitant medications, tamoxifen (10 mg/tablet, 1 tablet/time) was orally administered twice per day during the whole study period.

DRUG

ZOLADEX® 3.6 mg

ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, tamoxifen (10 mg/tablet, 1 tablet/time) was orally administered twice per day during the whole study period.

Trial Locations (1)

Unknown

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Luye Pharma Group Ltd.

INDUSTRY

NCT05110170 - Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX® | Biotech Hunter | Biotech Hunter